| Literature DB >> 23899075 |
Christine R Herman1, Karen J Buth, Jean-François Légaré, Adrian R Levy, Roger Baskett.
Abstract
BACKGROUND: Quality improvement initiatives in cardiac surgery largely rely on risk prediction models. Most often, these models include isolated populations and describe isolated end-points. However, with the changing clinical profile of the cardiac surgical patients, mixed populations models are required to accurately represent the majority of the surgical population. Also, composite model end-points of morbidity and mortality, better reflect outcomes experienced by patients.Entities:
Mesh:
Year: 2013 PMID: 23899075 PMCID: PMC3751077 DOI: 10.1186/1749-8090-8-177
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Model variable definitions
| Age | Patient age at the time of surgery |
| Gender | Male or Female |
| Body mass index | Calculated in kilograms and centimeters. |
| Diabetes | Any history of Diabetes Mellitus, regardless of duration |
| Pre-op Afib | Any previously documented history of Atrial Fibrillation |
| COPD | Any preivous documented history of Chronic Obstructive Pulmonary Disease |
| CVD | Any Transient Ischemic Attack, Cerebrovascular Accident/Stroke, history of cerebrovascular surgery, or any carotid disease. |
| PVD | Whether the patient has Peripheral Vascular Disease, as indicated by claudication; amputation for arterial insufficiency; aorto-iliac occlusive disease reconstruction; peripheral vascular bypass surgery, angioplasty, or stent; documented AAA. |
| Frailty | Any deficiency in the Katz index of Activities of Daily Living (independence in feeding, bathing, dressing, transferring, toileting, and urinary continence), as well as independence in ambulation (no walking aid or assist required) or any clear evidence of a previous diagnosis of dementia by a physician. |
| EF<40 | Ejection fraction measured less than 40% by any modality. |
| NYHA (I-IV) | New York Heart Association Class. I = Patients with cardiac disease but without limitation of physical activity. II = Patients with cardiac disease resulting in slight limitation of physical activity (fatigue, palpitations, dyspnea, or anginal pain). III = Patients with cardiac disease resulting in marked limitation of physical activity. IV = Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. |
| Hemoglobin | Most recent hemoglobin level prior to day of surgery. |
| Pre-op creatinine | Highest preop serum creatinine for this admission. |
| Redo sternotomy | Any history of previous surgery that traversed the anterior mediastinum. |
| Surigical priority | Elective [stable at home], in-house [requiring hospitalization until the time of surgery], urgent [requiring surgery within 24 hours to minimize further clinical deterioration], or emergent [no delay in surgery]. |
| Procedure | Any Coronary artery bypass grafting, aortic valve replacement or repair with/without CABG, or Mitral valve replacement or repair with/without CABG. |
Distribution of risk factors in the model development cohort
| | |||||
|---|---|---|---|---|---|
| | | ||||
| Age | | 67 (IQR 59–74) | 66 (IQR 58–73) | 67 (IQR 57–75) | 74 (IQR 67–80) |
| Female | | 25 | 21 | 39 | 31 |
| BMI (kg/m2) | <25 | 22 | 20 | 28 | 26 |
| | 25-30 | 40 | 40 | 41 | 43 |
| | 30-35 | 25 | 27 | 18 | 23 |
| | >35 | 13 | 13 | 13 | 8 |
| Diabetes | | 36 | 40 | 23 | 34 |
| Pre-op Afib | | 12 | 9 | 21 | 22 |
| COPD | | 15 | 14 | 18 | 17 |
| CVD | | 14 | 14 | 13 | 17 |
| PVD | | 17 | 19 | 7 | 18 |
| Frailty | | 4 | 3 | 6 | 8 |
| EF<40 | | 15 | 15 | 11 | 20 |
| NYHA | I | 35 | 44 | 13 | 13 |
| | II | 23 | 23 | 29 | 21 |
| | III | 26 | 20 | 42 | 42 |
| | IV | 15 | 13 | 17 | 24 |
| HGB (g/L) | <115 | 50 | 52 | 49 | 38 |
| | 115-135 | 33 | 32 | 32 | 41 |
| | >135 | 17 | 15 | 19 | 21 |
| Pre-op creatinine | <115 | 74 | 76 | 78 | 62 |
| (μmol/L) | 115-140 | 14 | 13 | 12 | 18 |
| | 140-160 | 5 | 5 | 3 | 8 |
| | >160 | 7 | 7 | 7 | 11 |
| Redo sternotomy | | 7 | 4 | 19 | 11 |
| Status | Elective | 47 | 44 | 59 | 44 |
| | In-house | 41 | 41 | 36 | 43 |
| | Urgent | 9 | 11 | 4 | 10 |
| Emergent | 3 | 4 | 2 | 3 |
BMI Body mass index, HGB Hemoglobin, Afib Atrial Fibrillation, COPD Chronic Obstructive Pulmonary Disease, CVD Cerebro Vascular Disease, PVD Peripheral Vascular Disease, EF Ejection Fraction, NYHA New York Heart Association.
Frequency of MACE and MACE components in the model development cohort
| | |||||
|---|---|---|---|---|---|
| | | ||||
| MACE* | | 15.7 | 13.0 | 14.0 | 32.0 |
| Mortality | | 4.2 | 3.3 | 3.3 | 11.5 |
| Acute renal failure | | 6.5 | 5.5 | 5.5 | 14.0 |
| Any stroke | | 2.9 | 2.3 | 2.4 | 7.3 |
| | Transient (<24 h) | 1.7 | 0.9 | 1.2 | 3.1 |
| | Permanent | 1.7 | 1.4 | 1.3 | 4.2 |
| Infection | | 8.0 | 7.1 | 6.3 | 16.1 |
| | Deep sternal Wound infection | 1.1 | 1.0 | 0.1 | 2.9 |
| | Sepsis | 2.8 | 2.4 | 1.9 | 7.3 |
| Pneumonia | 6.5 | 5.7 | 5.3 | 13.6 |
*MACE—Major Adverse Cardiac Event defined as in-hospital death, stroke (persisting at discharge or transient), acute renal failure (new post-operative renal failure or acute on chronic (>50% increase from baseline creatinine)), or infection (sepsis, pneumonia, or deep sternal wound infection).
Logistic regression for MACE in a CABG/Valve population
| Age square | | 1.025 | 1.02-1.03 |
| Female | | 0.8 | 0.6-1.0 |
| PVD | | 1.6 | 1.2-1.9 |
| Frailty | | 1.7 | 1.2-2.5 |
| BMI | 25-30 | 1.0 | - |
| <25 | 1.2 | 0.9-1.5 | |
| 30-35 | 1.2 | 0.9-1.5 | |
| >35 | 1.5 | 1.1-2.1 | |
| NYHA I | | 1.0 | - |
| NYHA II | | 1.2 | 0.9-1.6 |
| NYHA III | | 1.2 | 0.9-1.5 |
| NYHA IV | | 1.3 | 1.0-1.8 |
| HGB <115 | | 1.2 | 1.0-1.5 |
| HGB 115-135 | | 1.8 | 1.3-2.3 |
| HGB >135 | | 1.0 | - |
| Creatinine | <115 | 1.0 | - |
| 115-140 | 1.3 | 1.1-1.7 | |
| 140-160 | 1.6 | 1.1-2.2 | |
| >160 | 1.6 | 1.2-2.2 | |
| Preop Afib | | 1.4 | 1.1-1.8 |
| Diabetes | | 1.5 | 1.1-1.8 |
| EF < 40 | | 1.3 | 1.0-1.7 |
| COPD | | 1.2 | 0.9-1.5 |
| CVD | | 1.2 | 1.0-1.6 |
| HTN | | 1.1 | 0.9-1.5 |
| Preop RF | | 1.3 | 0.9-1.9 |
| Procedure | CABG | 1.0 | - |
| Valve | 1.2 | 0.9-1.5 | |
| CABG + Valve | 2.3 | 1.8-3.0 | |
| Surgical priority elective | | 1.0 | - |
| In-house | 1.1 | 0.9-1.5 | |
| Urgent | 1.8 | 1.8-3.6 | |
| Emergent | 4.3 | 2.9-7.4 | |
| Redo | 1.4 | 0.9-1.9 |
Figure 1Calibration plot of observed risk versus predicted risk.